Answer
Sep 01, 2026 - 11:27 AM
Rinvoq (upadacitinib) is currently protected by patents, with the main patent in the United States expected to expire in December 2033. Generic versions of Rinvoq are unlikely to become available in the US before that date.
However, a generic is available at Universal Drugstore through our international pharmacy partners.
However, a generic is available at Universal Drugstore through our international pharmacy partners.
